Literature DB >> 8996189

Cloning, expression and pharmacological characterization of rabbit adenosine A1 and A3 receptors.

R J Hill1, J J Oleynek, C F Hoth, M A Kiron, W Weng, R T Wester, W R Tracey, D R Knight, R A Buchholz, S P Kennedy.   

Abstract

The role of adenosine A1 and A3 receptors in mediating cardioprotection has been studied predominantly in rabbits, yet the pharmacological characteristics of rabbit adenosine A1 and A3 receptor subtypes are unknown. Thus, the rabbit adenosine A3 receptor was cloned and expressed, and its pharmacology was compared with that of cloned adenosine A1 receptors. Stable transfection of rabbit A1 or A3 cDNAs in Chinese hamster ovary-K1 cells resulted in high levels of expression of each of the receptors, as demonstrated by high-affinity binding of the A1/A3 adenosine receptor agonist N6-(4-amino-3-[125I]iodobenzyl)adenosine (125I-ABA). For both receptors, binding of 125I-ABA was inhibited by the GTP analog 5'-guanylimidodiphosphate, and forskolin-stimulated cyclic AMP accumulation was inhibited by the adenosine receptor agonist (R)-phenylisopropyladenosine. The rank orders of potency of adenosine receptor agonists for inhibition of 125I-ABA binding were as follows: rabbit A1, N6-cyclopentyladenosine = (R)-phenylisopropyladenosine > N-ethylcarboxamidoadenosine > or = I-ABA > or = N6-2-(4-aminophenyl) ethyladenosine > > N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide > N6-(4-amino-3-benzyl)adenosine; rabbit A3, N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide > or = I-ABA > > N-ethylcarboxamidoadenosine > N6-2-(4-aminophenyl) ethyladenosine = N6-cyclopentyladenosine = (R)-phenylisopropyladenosine > N6-(4-amino-3-benzyl)adenosine. The adenosine receptor antagonist rank orders were as follow: rabbit A1, 8-cyclopentyl-1,3-dipropylxanthine > 1,3- dipropyl-8-(4-acrylate)phenylxanthine > or = xanthine amine congener > > 8-(p-sulfophenyl)theophylline; rabbit A3, xanthine amine congener > 1,3-dipropyl-8-(4-acrylate)phenylxanthine > or = 8-cyclopentyl-1,3-dipropylxanthine > > 8-(p-sulfophenyl)theophylline. These observations confirm the identity of the expressed proteins as A1 and A3 receptors. The results will facilitate further in-depth studies of the roles of A1 and A3 receptors in adenosine-mediated cardioprotection in rabbits, which can now be based on the appropriate recombinant rabbit A1 and A3 receptor pharmacology.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8996189

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  The adenosine metabolite inosine is a functional agonist of the adenosine A2A receptor with a unique signaling bias.

Authors:  Ajith A Welihinda; Manmeet Kaur; Kelly Greene; Yongjiao Zhai; Edward P Amento
Journal:  Cell Signal       Date:  2016-02-19       Impact factor: 4.315

2.  A novel cardioprotective function of adenosine A1 and A3 receptors during prolonged simulated ischemia.

Authors:  K Stambaugh; K A Jacobson; J L Jiang; B T Liang
Journal:  Am J Physiol       Date:  1997-07

3.  Negative regulation of CFTR activity by extracellular ATP involves P2Y2 receptors in CFTR-expressing CHO cells.

Authors:  B Marcet; V Chappe; P Delmas; M Gola; B Verrier
Journal:  J Membr Biol       Date:  2003-07-01       Impact factor: 1.843

4.  The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel.

Authors:  Tina C Wan; Zhi-Dong Ge; Akihito Tampo; Yasushi Mio; Martin W Bienengraeber; W Ross Tracey; Garrett J Gross; Wai-Meng Kwok; John A Auchampach
Journal:  J Pharmacol Exp Ther       Date:  2007-09-28       Impact factor: 4.030

Review 5.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.

Authors:  B B Fredholm; A P IJzerman; K A Jacobson; K N Klotz; J Linden
Journal:  Pharmacol Rev       Date:  2001-12       Impact factor: 18.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.